The material contained on this Web site is provided for informational purposes only and does not constitute legal advice. The publication and receipt of any information contained on this Web site does not create an attorney-client relationship with Barash Law LLC or with any of our attorneys. Readers should not act upon any information on this site without seeking professional legal counsel. While the information on this Web site is maintained and periodically updated for accuracy, this information may contain omissions or errors for which we disclaim any and all liability.
Barash Law LLC does not collect identifying information from visitors to its Web site unless the information is provided by the visitor or the visitor's internet browser. We will only respond to direct inquiries, and will use information collected from internet browsers for the sole purpose of monitoring Web site usage. We do not share Web site data with outside third-parties. Barash Law LLC is not responsible for the privacy practices or content of any links to other Web sites contained in our Firm’s Web site.
If you have any questions or concerns regarding this Privacy Statement, please contact us at email@example.com
Emergency Use Authorizations as we know them now were borne out of the terror attacks on 9/11 and subsequent anthrax mail incidents and came into law in 2004 and have been amended in 2013 and again in 2016. As of 1/1/2021, two vaccines have been authorized for use in the United States, each under an EUA. This talk will explore the history of the EUA, the changes made to the EUA, and how it is being utilized today. The talk will also discuss the differences between EUAs and Approvals as well as the federal government’s absorption of damages from vaccine injuries – who and what is covered and what are the limitations.
This presentation will discuss the basics of pharmaceutical solid forms and why they are important in drug development and repurposing programs. The emergence of AI may also have a great impact in the near future on patent strategies, and Eyal will discuss how we can forecast now about how to go about such patent strategies.